Altimmune Commences Dosing in Phase 1 Clinical Trial of ALT-801, a Long-Acting GLP-1/Glucagon Receptor Dual Agonist for the Treatment of NASH

Stock Information for Altimmune Inc.

Loading

Please wait while we load your information from QuoteMedia.